**NEUROTENSINOMAS**

**Aaron Vinik, MD, PhD,** Murray Waitzer Endowed Chair in Diabetes Research, Professor of Medicine/Pathology/Neurobiology, Director of Research and Neuroendocrine Unit, Division of Endocrine and Metabolic Disorders, Eastern Virginia Medical School, Norfolk, VA. vinikai@evms.edu

Received 29 May 2017

## ABSTRACT

Neurotensin (NT) is a 13 amino acid polypeptide first extracted from bovine brain subsequently isolated from the human GI tract. Neurotensin has a number of interesting pharmacologic effects that include hypotension, tachycardia, and cyanosis and stimulation of secretion from the small intestine. It also has been reported to inhibit the interdigestive myoelectric complex and stimulate insulin release. NT also increases venous vascular permeability, raises blood glucose, and lowers blood pressure. High concentrations of NT-like immunoreactivity (NTLI) are localized to a specific “N” cell in the jejunum. Plasma concentrations rise after food ingestion, and high circulating levels have been found after surgery for duodenal ulcer and jejunoileal bypass for obesity. No clear physiologic role has been established for the peptide. High circulating levels also have been found in patients with VIPomas. The clinical features of reported cases include diarrhea, hypotension, hypokalemia, edema, weight loss, and, occasionally, diabetes. It can mimic the Vipoma syndrome comprising WDHHA ( watery diarrhea, hypotension, hypokalemia and acidosis). Surgical removal cures about 50% of cases and tumors are sensitive to streptozotocin.

Neurotensin (NT) is a 13 amino acid polypeptide first extracted from bovine brain by Carraway and Leeman (1). It subsequently was isolated from the human GI tract and found to have the same amino acid sequence as that in brain (2). Neurotensin has a number of interesting pharmacologic effects that include hypotension, tachycardia, and cyanosis (3) (4) and stimulation of secretion from the small intestine (5). It also has been reported to inhibit the interdigestive myoelectric complex and stimulate insulin release (6). NT also increases venous vascular permeability, raises blood glucose, (7) (8) (9) and lowers blood pressure (1) (4).

High concentrations of NT-like immunoreactivity (NTLI) are present in the ileal mucosa, where it is localized to a specific “N” cell (10). Plasma concentrations rise after food ingestion (11), and high circulating levels (12) have been found after surgery for duodenal ulcer and jejunoileal bypass for obesity (13). No clear physiologic role has been established for the peptide. High circulating levels also have been found in patients with VIPomas (14-18). (Assay available at Inter Science Institute-800-255-2873).

In 1981, based on the pharmacologic actions of NT, it was predicted (19) that a syndrome of excess would emerge, presenting with features that are consonant with the pharmacologic actions of the peptide: diabetes, hypotension, vasodilatation, cyanosis, and edema. In addition to these features, investigation would reveal net secretion of fluid and electrolytes, inhibition of gastric acid secretion, infrequent interdigestive myoelectric complexes, and prolonged biologic reaction of gastric emptying. The prediction that diabetes would occur was based on the predominant stimulation of adrenomedullary secretions despite stimulation of insulin secretion (20). The clinical features of reported cases include diarrhea, hypotension, hypokalemia, edema, weight loss, and, occasionally, diabetes (21) (19).

Apart from these reported cases, Blackburn and colleagues (22) examined plasma NT levels in 326 fasting patients with tumors in a variety of sites. Of these patients, 180 had tumors of the pancreas, including glucagonomas (23), gastrinomas (24), insulinomas (25), nonsecretory tumors (26), and VIPomas (27). Plasma NTLI levels were raised in only six patients with VIPomas and none with the other tumors. Twenty-one of the tumors containing VIP were removed surgically, and six were found to contain NTLI. The clinical features of these six patients did not appear to differ from those of the remaining 15 patients.

With so few cases, it is difficult to generalize on the clinical picture. Fifty percent of the cases were cured by resection of tumors in the pancreas (28) or lung, (29) and the remainder have responded well to streptozotocin. The syndrome appears to comprise diarrhea, diabetes, and weight loss; as such, it may not be readily distinguishable from the VIPoma syndrome.

Neurotensinomas probably are best characterized as yet another tumor that is capable of causing the WDHHA (watery diarrhea, hypokalemia, hypochlorhydria, and acidosis) syndrome. Edema, hypotension, and flushing should increase the suspicion of a neurotensinoma. Of interest the rise in the use of bariatric surgery in the treatment of obesity has generated clinical syndromes which mimic the above and it would be of interest to determine if neurotensin might be implicated.

## REFERENCES

1. Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 1973; 248(19):6854-6861.
2. Hammer RA, Leeman SE, Carraway R, Williams RH. Isolation of human intestinal neurotensin. J Biol Chem 1980; 255(6):2476-2480.
3. Hammer R, Leeman S. Neurotensin: properties and actions. In Gut Hormone. Edinburgh: Churchill Livingstone, 1981: 290.
4. Mitchenere P, Adrian TE, Kirk RM, Bloom SR. Effect of gut regulatory peptides of intestinal luminal fluid in the rat. Life Sci 1981; 29(15):1563-40.
5. Andersson S, Rosell S, Hjelmquist U, Chang D, Folkers K. Inhibition of gastric and intestinal motor activity in dogs by (Gln4) neurotensin. Acta Physiol Scand 1977; 100(2):231-235.
6. Blackburn AM, Fletcher DR, Bloom SR et al. Effect of neurotensin on gastric function in man. Lancet 1980; 1(8176):987-989.
7. Feldman JM. Carcinoid tumors and the carcinoid syndrome. Curr Probl Surg 1989; 26(12):835-885.
8. Carraway RE, Demers LM, Leeman SE. Hyperglycemic effect of neurotensin, a hypothalamic peptide. Endocrinology 1976; 99(6):1452-1462.
9. Nagai K, Frohman LA. Hyperglycemia and hyperglucagonemia following neurotensin administration. Life Sci 1976; 19(2):273-279.
10. Polak JM, Sullivan SN, Bloom SR et al. Specific localisation of neurotensin to the N cell in human intestine by radioimmunoassay and immunocytochemistry. Nature 1977; 270(5633):183-184.
11. Johnson JA, Fabri PJ, Lott JA. Serum gastrins in Zollinger-Ellison syndrome: identification of localized disease. Clin Chem 1980; 26(7):867-870.
12. Blackburn AM, Bloom SR. A radioimmunoassay for neurotensin in human plasma. J Endocrinol 1979; 83(2):175-181.
13. Besterman HS, Bloom SR, Sarson DL et al. Gut-hormone profile in coeliac disease. Lancet 1978; 1(8068):785-788.
14. Feurle GE, Helmstaedter V, Tischbirek K et al. A multihormonal tumor of the pancreas producing neurotensin. Dig Dis Sci 1981; 26(12):1125-1133.
15. Gutniak M, Rosenqvist U, Grimelius L et al. Report on a patient with watery diarrhoea syndrome caused by a pancreatic tumour containing neurotensin, enkephalin and calcitonin. Acta Med Scand 1980; 208(1-2):95-100.
16. Maier W, Schumacher KA, Etzrodt H, Arlart I. An neurotensinoma of the head of the pancreas. Demonstration by ultrasound and computed tomography. Eur J Radiol 1982; 2(2):125-127.
17. Shulkes A, Boden R, Cook I, Gallagher N, Furness JB. Characterization of a pancreatic tumor containing vasoactive intestinal peptide, neurotensin, and pancreatic polypeptide. J Clin Endocrinol Metab 1984; 58(1):41-48.
18. Wood JR, Wood SM, Lee YC, Bloom SR. Neurotensin-secreting carcinoma of the bronchus. Postgrad Med J 1983; 59(687):46-47.
19. Vinik A, Glaser B. Pancreatic endocrine tumors. Pancreatic Disease. New York: Grune & Stratton, 1981: 427.
20. Brown M, Vale W. Effects of neurotensin and substance P on plasma insulin, glucagon and glucose levels. Endocrinology 1976; 98(3):819-822.
21. Vinik AI, Achem-Karam S, Owyang C. Gastrointestinal hormones in clinical medicine. Spec Top Endocrinol Metab 1982; 4:93-138.
22. Blackburn AM, Bryant MG, Adrian TE, Bloom SR. Pancreatic tumours produce neurotensin. J Clin Endocrinol Metab 1981; 52(4):820-822.
23. Pipeleers D, Couturier E, Gepts W, Reynders J, Somers G. Five cases of somatostatinoma: clinical heterogeneity and diagnostic usefulness of basal and tolbutamide-induced hypersomatostatinemia. J Clin Endocrinol Metab 1983; 56(6):1236-1242.
24. Roos BA, Lindall AW, Ells J, Elde R, Lambert PW, Birnbaum RS. Increased plasma and tumor somatostatin-like immunoreactivity in medullary thyroid carcinoma and small cell lung cancer. J Clin Endocrinol Metab 1981; 52(2):187-194.
25. Krejs GJ, Orci L, Conlon JM et al. Somatostatinoma syndrome. Biochemical, morphologic and clinical features. N Engl J Med 1979; 301(6):285-292.
26. Crain EL, Jr., Thorn GW. Functioning pancreatic islet cell adenomas; a review of the literature and presentation of two new differential tests. Medicine (Baltimore) 1949; 28(4):427-447.
27. Bloom SR, Mortimer CH, Thorner MO et al. Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone. Lancet 1974; 2(7889):1106-1109.
28. Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955; 142(4):709-723.
29. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960; 39:1157-1175.